Cue Biopharma says CUE — 221 Phase 2 trial in chronic spontaneous urticaria meets primary endpoint

Cue Biopharma reported positive topline Phase 2 results for CUE-221 in chronic spontaneous urticaria, meeting primary and key secondary goals. Responses strengthened beyond the main assessment window, with benefit persisting for months in the highest-dose group following treatment completion. Results suggested a different efficacy pattern versus Xolair, supporting a potential mechanism-based differentiation with strategic implications for positioning. Safety profile appeared favorable, with no treatment-related serious events reported and no anaphylaxis observed in the study. Full results, including pharmacokinetic and IgE analyses, will be presented at a future scientific meeting; investor call set for Sept. 21. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via (Ref. ID: 202609200600PRIMZONEFULLFEED9830110) on September 20, 2026, and is sole